Full-Time

Project Manager

Posted on 9/27/2025

Icon

Icon

10,001+ employees

Global drug and device development services

No salary listed

Burlington, ON, Canada

Remote

Home based in Canada.

Category
Business & Strategy (1)
Requirements
  • Relevant operational clinical trial experience
  • A scientific or technical degree is preferred along with knowledge of clinical trial methodology
  • BA/BS 5+ years of relevant experience
  • MBA/MS/ 3+ years of relevant experience
  • BS/BSc/MS/MSc
  • Working knowledge of Good Clinical Practice, clinical and regulatory operations and environment in countries under responsibility
  • English is required.
Responsibilities
  • Responsible for management/oversight of study and regional/country level activities from study startup through conduct and study close
  • May manage the study start up process in countries assigned (where SUPM not assigned) and/or oversee pCRO responsible for these activities as applicable
  • Through the Site Care Partner/Country Trial Manager or pCRO supports the Country/investigator outreach process, site identification and feasibility ensuring countries/sites can meet all study protocol requirements
  • Provides country level input on Startup and Recruitment milestones as provided by pCRO and/or Country Trial Manager/Site Care Partner to Global Study Manager during planning
  • Is accountable for overseeing pCRO and/or Country Trial Manager/Site Care Partner for assigned studies at country level in accordance with the overall project plan, manages and maintains accurate country level plans (e.g. timelines, budget, risk and quality plans)
  • Collaborates with accountable roles to identify and manage deviations and risks in study startup and execution and implements mitigation strategies as required. Is also accountable for resolution of Site Activation escalations to Study Teams including offering options for mitigation
  • Leader of the Local Study Team (core members: (Lead) Site Care Partners Clinical Trial Assistant, ad hoc members: ICL, Site Activation Partner, CTRO and Local Regulatory, Medical Affairs colleagues and other key stakeholders as required)
  • Ensures compliance to relevant Global and Local, internal and external requirements and regulations
  • Ensures timely communication bidirectionally between the global and local study team
  • Provides protocol level guidance and support to responsible Local Study Team members as applicable
  • Liaise with Site Care Partner, Lead Site Care Partner, Site Activation Partners and Regulatory colleagues in country to agree on submission strategy to Health Authorities and Ethic Committees
  • Utilizes roles in country such as Lead Site Care Partner, and expert roles such as Contracts Leads, Site Activation Partners to provide the Global Teams with local intelligence and operational nuances to be considered
  • Acts as the study level point of contact for all study-level questions for the Local Study Team, ensuring resolution at lowest possible level, and when needed liaising with and escalating to appropriate global roles/teams
  • Follows up on region/country level issue status to ensure resolution
  • Identifies country level trends to improve deliverables processes as needed
  • Utilizes country intelligence to provide input on country specific risks into preparation of Investigational Quality Management Plan, Study Monitoring Plans, ensures PTMF completeness and oversight of all relevant compliance activities for allocated studies
  • Ensures audit/Inspection readiness during start-up and conduct
  • Manages applicable Quality Events with pCRO and local team as applicable and required
  • Coordinates effective site recruitment planning to allow for implementation of plans at the country and site level, consistent with global plan and local targets
  • Responsible to drive and ensure delivery of data cleaning deliverables for pCRO and sites as applicable
  • Provides input on Country level Per Subject Costs, local vendor costs and other fees where applicable
  • May act as a Subject Matter Expert
  • May lead operational effectiveness initiatives at country or regional level
  • Responsible for PTA and SIV report review for reports completed by the Site Care Partner
  • Supports implementation of Pfizer's Site Technology Experience systems (e.g. Shared Investigator Platform SIP, Centralized Account Management CAM)
  • Support to EC/RA and other relevant (e.g. radiation, biobank) submissions and deficiency/query responses for initial and subsequent CTA submissions within required timelines
  • Drives pCRO and/or applicable internal study team members to ensure PTMF set up meets study requirements, and maintains oversight of PTMF completeness
  • Provides country level documents to PTMF and maintains oversight of Investigator Site File (ISF) reconciliation and completeness actions
  • Ensures pCRO and/or applicable internal study team members maintain appropriate level IP/equipment/ancillary supplies management including Import/Export License management with the support of Clinical Trial Assistants and other roles as required
  • Supports implementation of new tools and technologies (e.g. eConsent, eISF, Remote Source Access, remote SDV/SDR, iConnect, implementation of protocol required decentralized trial options etc.)
  • Support Identification, contract development and management of local vendors or facilities as per protocol
  • Investigator Meeting support and management including doing presentations as appropriate
  • Management of local Investigator Meetings including doing presentations as appropriate
Desired Qualifications
  • Extensive global clinical trial/study management experience
  • Working knowledge of Good Clinical Practices, monitoring, clinical and regulatory operations
  • Prior Experience Preferred:
  • Demonstrated study management / leadership experience
  • Demonstrated oversight of CROs
  • Demonstrated experience in managing Per Subject Costs, vendor & ancillary, and monitoring costs projections & spend

Provides consulting, development, and commercialization services for drugs and medical devices through a global network to help clients accelerate development and bring products to market. A global team of experts in 53 countries offers end-to-end support across strategy, development, regulatory, manufacturing, and market access to reduce time to market, lower costs, and improve quality. The company differentiates itself with its large global presence, clear focus on speed and cost, and extensive experience across therapeutic areas. Its goal is to help clients accelerate the development of life-saving drugs and devices by delivering high-quality information, solutions, and performance.

Company Size

10,001+

Company Stage

IPO

Headquarters

Ireland

Founded

1990

Simplify Jobs

Simplify's Take

What believers are saying

  • Advarra integration reduces administrative friction and accelerates study startups.
  • Oncology expansion adds 14 oncologists to boost patient recruitment.
  • Jefferies upgrades ICON to Buy with $135 target post-selloff.

What critics are saying

  • Audit probe reveals $160M revenue overstatements, delaying Q4 2025 results to April 30.
  • Holzer & Holzer, Levi & Korsinsky lawsuits erode investor confidence immediately.
  • IQVIA captures 20% more biotech trials via superior AI site selection.

What makes Icon unique

  • ICON partners with Advarra on March 24, 2026, for connected site network using Braid AI.
  • Accellacare expands oncology via Brian Moran Cancer Institute partnership in Illinois.
  • Deepali Suri leads biotech division since September 2025 with AI-enabled solutions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

Mental Health Support

Life Insurance

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-13%

1 year growth

-13%

2 year growth

-13%
Resonate Group
Mar 24th, 2026
Icon, Advarra partnership aims to optimize trials, expand access.

Icon, Advarra partnership aims to optimize trials, expand access. * March 24, 2026 Clinical research organization Icon has entered into a partnership with research technology company Advarra to launch a network of connected sites for clinical trials. Fields (*) Mark are Required

Business Wire
Mar 24th, 2026
ICON and Advarra launch connected site network to streamline clinical trials

ICON plc and Advarra have partnered to introduce a "research-ready" connected site network model for clinical trials. The partnership integrates ICON's global clinical trial solutions with Advarra's site systems, already used by over 50,000 investigators worldwide, including researchers at 90 of the top 125 academic medical centres. The collaboration will create a shared operating environment that reduces administrative burden, accelerates study startup and increases clinical trial participation. Advarra will provide operational intelligence through its Braid AI platform to help ICON optimise protocol design and improve site identification. The companies plan to equip emerging and research-naïve sites with Advarra's technology, enabling broader geographic diversity in clinical trials. Last year, Advarra's systems managed over $4 billion in trial invoice value and three million patient visits.

Contract Pharma
Mar 24th, 2026
ICON, Advarra partner on connected site network model.

ICON, Advarra partner on connected site network model. Partnership will integrate ICON's global clinical trial services with Advarra's site CTMSs, eISF, and eSource systems. March 24, 2026 Managing Editor, Contract Pharma ICON plc, a clinical research organization, and Advarra, a provider of connected, intelligence-powered research technology, have entered a partnership agreement to introduce a new 'research-ready,' connected site network model for clinical trials. The partnership will integrate ICON's global clinical trial services with Advarra's site CTMSs, eISF, and eSource systems. This approach leverages Advarra's Study Collaboration as the connector to ICON's technology to create a shared operating environment for ICON studies that aims to reduce administrative friction, accelerate study startup, and increase clinical trial participation. Advarra will also provide ICON with operational intelligence through Study Collaboration, built on Braid, Advarra's data and AI platform that draws on operational insights from its IRB and clinical trial systems. The intelligence will help ICON further optimize protocol design, improve forecasting and study planning, and strengthen research site identification and feasibility decisions. With a clearer understanding of research site capacity, workflow realities, and historical operational patterns, the goal is to allow for studies to be planned more realistically and executed with fewer downstream adjustments. In addition, ICON and Advarra will work together to expand access to clinical trials by enabling more research sites worldwide to support today's increasingly complex study requirements. The companies plan to equip emerging and research-naïve sites, along with select sites working with ICON, with Advarra's site technology, helping standardize operations and reduce manual processes. "Research sites should not have to adapt their operations for every new study or sponsor, and ICON and Advarra are focused on meeting sites where they are, prioritising their needs and removing that burden through this partnership," said Barry Balfe, CEO of ICON plc. "By aligning ICON's workflows with the systems sites already use every day, we're advancing a more practical and scalable way to run trials that reduces administrative burden on sites." "Sites do their best work when they can stay focused on patients and study delivery, not on managing fragmented processes," said Gadi Saarony, CEO of Advarra. "By integrating ICON's technology with the Advarra systems sites already use, this partnership allows sites to work in their native systems, reducing rework, improving consistency, and streamlining workflows. For sponsors, it means trials can move forward with greater speed and confidence, helping promising therapies move through development more efficiently and reach patients sooner."

Yahoo Finance
Mar 5th, 2026
Jefferies upgrades ICON to buy as accounting probe selloff deemed overdone

Jefferies has upgraded ICON Public Limited Company to Buy from Hold, lowering its price target to $135 from $175. Analyst David Windley cited the stock's valuation as "hard to ignore", noting that whilst AI could compress labour-intensive businesses, the market may underestimate regulatory hurdles to rapid tech adoption. The upgrade follows TD Cowen's recent move to Buy from Hold with a $120 price target, describing the risk-reward as "compelling" after a 33% selloff tied to an internal accounting investigation. ICON disclosed in February that preliminary findings indicate revenue for 2023 and 2024 may have been overstated by less than 2% each year. The company withdrew its 2025 guidance and plans to release fourth-quarter results by 30th April.

PR Newswire
Feb 18th, 2026
ICON plc shares drop 40% after internal probe uncovers $160M annual revenue overstatement

ICON plc, one of the world's largest contract research organisations, is facing investigation after disclosing on 12 February that an internal accounting probe uncovered preliminary evidence of revenue overstatements by up to 2% in fiscal years 2023 and 2024. The disclosure prompted the company to delay releasing its fourth-quarter and full-year 2025 financial results. With reported annual revenue exceeding $8 billion, a 2% overstatement would represent approximately $160 million per year. Following the announcement, ICON shares declined roughly 40%, erasing billions in market capitalisation. Law firm Levi & Korsinsky is investigating the Dublin-based company, which provides outsourced drug development and clinical trial management services. During 2025, ICON repurchased $750 million of its own shares and authorised an additional $1 billion buyback programme.

INACTIVE